About: Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay
Creator	Holbro, Andreas Battegay, Manuel Simmons, Graham Hanson, Carl Corash, Laurence Buser, Andreas Bagri, Anil Danh, Kenneth Karp, Donna Robinson, Peter Schreiber, Martin Seftel, David Tsai, Cheng-Ting
Source	MedRxiv; Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more than 4 million confirmed infections worldwide and over 300,000 deaths. While Remdesivir has recently received FDA emergency use authorization for treatment of SARS-CoV-2 infection, convalescent plasma (CP) with high titers of SARS-CoV-2 neutralizing antibodies (NAbs) from recovered donors remains a promising and widely accessible method to mitigate severe disease symptoms. Here, we describe the development and validation of a cell-free neutralization PCR assay using SARS-CoV-2 spike protein S1 and human ACE2 receptor-DNA conjugates. By comparing with samples collected prior to the outbreak, we confirmed that NAbs were specifically detected in COVID-19 cases. Using our unique assay, the NAb signals are detectable as early as 10 days after onset of symptoms and continue to rise, plateauing after 18 days. Notably, we showed that the use of a licensed pathogen reduction technology to inactivate potentially contaminating infectious pathogens in CP did not alter NAb signals, paving a path to safely administer effective CP therapies. The described neutralization PCR assay can serve as a qualification tool to easily identify suitable CP donors of a potentially lifesaving therapy. In addition, this assay tool is readily deployable in standard laboratories with biosafety level 2 capability, and can yield results within 2–3 hrs. This advancement can facilitate research on factors driving diverse COVID-19 disease manifestations, help evaluate the impact of various CP processing protocols on CP therapeutic efficacy and assist in accelerating vaccine efficacy assessment.
has issue date	2020-06-02(xsd:dateTime)
bibo:doi	10.1101/2020.05.28.20105692
bibo:pmid	32577696
has license	cc-by-nc-nd
sha1sum (hex)	52ff4879de1331fa687d9d54726383156fdf482e
schema:url	https://doi.org/10.1101/2020.05.28.20105692
resource representing a document's title	Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay
has PubMed Central identifier	PMC7302305
has PubMed identifier	32577696
schema:publication	medRxiv
resource representing a document's body	covid:52ff4879de1331fa687d9d54726383156fdf482e#body_text
is schema:about of	named entity 'assay' named entity 'infections' named entity 'certified' named entity 'assay' named entity 'International' named entity 'detectable' named entity 'high' named entity 'AVAILABLE' named entity 'DIVERSE' named entity 'OUR' named entity 'CONJUGATES' named entity 'COMPARING' named entity 'led' named entity 'signals' named entity 'convalescent' named entity 'assay' named entity 'accelerating' named entity 'SARS-CoV-2' named entity 'neutralization' named entity 'continue' named entity 'neutralizing antibodies' named entity 'This' named entity 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'mitigate' named entity 'deployable' named entity 'tool' named entity 'donors' named entity 'tool' named entity 'promising' named entity 'NAb' named entity 'recovered' named entity 'CC-BY-NC-ND' named entity 'laboratories' named entity 'pathogens' named entity 'emergency use authorization' named entity 'spike protein' named entity 'preprint' named entity 'NAb' named entity 'PCR' named entity 'SARS-CoV-2' named entity 'neutralizing antibodies' named entity 'Mars' named entity 'license' named entity 'preprint' named entity 'sodium chloride' named entity 'PRNT' named entity 'Protein' named entity 'ACE2' named entity 'complement' named entity 'Middle East Respiratory Syndrome' named entity 'ACE2' named entity 'COVID-19' named entity 'silver staining' named entity 'NAb' named entity 'ACE2' named entity 'blood donors' named entity 'virus' named entity 'pathogen inactivation' named entity 'medRxiv' named entity 'C-terminus' named entity 'H1N1' named entity 'PCR' named entity 'real-time PCR' named entity 'COVID' named entity 'effective competition' named entity 'barcode' named entity 'screening tests' named entity 'peer review' named entity 'neutralizing antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software